Accession Number : ADA337596
Title : Radioimmunotherapy of Metastatic Breast Cancer Using Radiolabeled Tumor Specific Antibodies.
Descriptive Note : Annual rept. 1 Sep 96-31 Aug 97
Corporate Author : NEW YORK UNIV MEDICAL CENTER NY
Personal Author(s) : Wasserheit, Carolyn
PDF Url : ADA337596
Report Date : SEP 1997
Pagination or Media Count : 54
Abstract : We have completed a radioimaging study of 111In-Mx-DTPAA-huBrE-3 in patients with metastatic breast cancer. The results suggest that a therapeutic trial of 9O-Y-Mx- DTPA huBrE-3 is feasible and repeated doses can be administered. We recently opened a therapeutic phase I study of dose fractionated 9O-Y-Mx-DTPA huBrE-3. Our preclinical experiments in the nude mouse model demonstrated that Topotecan enhances the therapeutic index of radioimmunotherapy against human mammary carcinoma. substituting a nonspecific MOPC antibody for BrE-3 did not result in an anti-tumor response indicating that specific binding of BrE-3 antibody to the tumor is necessary. A fractionated dose of BrE-3 resulted in a similar anti-tumor effect to one dose of BrE. In vitro studies demonstrated a decrease in cell proliferation rate and an increase in the apoptotic rate in the cells treated with Topotecan The MDA-MB 157 cells which are BrE-3 +1 demonstrated an additive effect on the apoptotic rate when treated with a combination of BrE-3 and Topotecan. The data generated thus far support the rationale for using this combined modality therapy in women with advanced breast cancer.
Descriptors : *NEOPLASMS, *CARCINOGENS, *RADIOACTIVE ISOTOPES, *MAMMARY GLANDS, *METASTASIS, *BREAST CANCER, RATES, IN VITRO ANALYSIS, DOSAGE, ANTIBODIES, INDEXES, MICE, CELLS(BIOLOGY), LABELED SUBSTANCES, ANATOMICAL MODELS.
Subject Categories : Anatomy and Physiology
Distribution Statement : APPROVED FOR PUBLIC RELEASE